Earlier this year, AAPS’ fully open access journal AAPS Open published Pharmacokinetics and biodistribution of a novel anticancer thyrointegrin αvβ3 antagonist: triazole modified tetraiodothyroacetic acid conjugated to polyethylene glycol (P-bi-TAT), by Kazutoshi Fujioka, Kavitha Godugu, and Shaker A. Mousa at the Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences.
Abstract
We previously developed a triazole modified tetraiodothyroacetic acid (TAT) conjugated to a polyethylene glycol (PEG)-based thyrointegrin αvβ3 antagonist targeted compound, called P-bi-TAT. It exhibited potent anti-angiogenic and anticancer activities in vivo. The objective of the current study is to develop a quantitative bioanalytical method for P-bi-TAT using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and to elucidate pharmacokinetics (PK) and biodistribution of P-bi-TAT in animals. We used in-source collision-induced dissociation (CID) for ionization of P-bi-TAT in the positive mode, followed by multiple reaction monitoring (MRM) for quantification. P-bi-TAT was quantified using P-mono-TAT as an internal standard because of its similarity in structure and physicochemical properties to P-bi-TAT. The LOQ for P-bi-TAT was 30 ng/μL and the recovery efficiency was 76% with the developed method. Cmax and AUC results at different doses (1, 3, 10 mg/kg) in rats suggest that P-bi-TAT is dose-dependent within the range administered. Results for Cmax and AUC in monkeys at a low dose (25 mg/kg) were comparable to those in rats. Biodistribution of subcutaneously administered P-bi-TAT in the brain of rats ranged from 7.90 to 88.7 ng/g brain weight, and levels of P-bi-TAT in the brain were dose-dependent. The results suggest that P-bi-TAT is a potential candidate as a molecular-targeted anticancer therapeutic with blood-brain barrier permeability and acceptable PK parameters. Its accumulation in organs, toxicokinetic, and pharmacodynamics needs to be further investigated.
Other recent AAPS PharmSci 360 programming related to this topic include:
Endothelial Targeted Nanodelivery of RhoA Kinase Inhibitors: Potential Impact on Tumor Angiogenesis and Metastasis Inhibition
Tumor-Specific Manipulation of Tumor-Associated Macrophages for Cancer Immunotherapy
Novel Sorafenib Granules Developed by Using In Situ Self-Assembling Nanoparticle Technology Enhanced Oral Absorption of Sorafenib
Development of a Biorelevant Dissolution Method for Oral Drug Formulation
Applications of Albumin Fusion Proteins as Drug Carriers and Therapeutics
Polymeric Micelle for Targeted Delivery of Paclitaxel to Breast Cancer
Read the full article for FREE and share with your colleagues! Learn more about AAPS Open and submit your article for peer review today.